Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment
Completed · Phase 1
Conditions studied: Focal Segmental Glomerulosclerosis (FSGS)
In brief
The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of Inaxaplin (IXP) in participants with mild or moderate hepatic impairment and in matched healthy participants.
Key facts
- Study ID
- NCT06529796
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 36
- Starts
- 2024-08-02
- Expected to finish
- 2024-12-20
- Last updated by the study team
- 2025-01-20
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- Division of Clinical Pharmacology, University of Miami — Miami, Florida, United States
- GCP Research — St. Petersburg, Florida, United States
- Texas Liver Institute — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.